ADC THERAPEUTICS — 2141279

Toolbar

Details

Application number

2141279

Registration number

TMA1315761

International Registration Number

1621298

Type(s)

Design

Category

Trademark

CIPO Status

REGISTERED

TM5 status

LIVE/REGISTRATION/Issued and Active
The trademark application has been registered with the Office.

Filed

2021-05-03

International Registration

2021-05-03

Registered

2025-05-23

Registration Expiry Date

2031-05-03

Registered Owner

ADC Therapeutics SA
Route de la Corniche, 3B
CH-1066 Epalinges
SWITZERLAND

Agent

OSLER, HOSKIN & HARCOURT LLP
Suite 320, World Exchange Plaza
100 Queen Street
Ottawa,
ONTARIO K1P1J9

Documents

Trademark description

The mark consists of the letters ADC above the word THERAPEUTICS; a wave element extends across the letter A to a shared edge of the letters D and C.

Index headings

  • ADC THERAPEUTICS
  • AD
  • A
  • D

Vienna information (Code & Description)

26.11.1
One line or one band
A 26.11.6
Thick lines, bands
A 26.11.8
Horizontal lines or bands
A 26.11.13
Wavy lines or bands, zigzag lines or bands
27.5.1
Letters presenting a special form of writing
A 27.5.11
Letters underlined, overlined, framed or barred by one or more strokes
A 27.5.8
Letters linked to or containing a figurative element -- Note: Letters representing a human being or a part of the human body, an animal or a part of an animal's body, a plant, a heavenly body, a natural phenomenon or an object are classified in division 27.3.
A 27.5.22
Monograms formed of intertwined, overlapping or otherwise combined letters
25.12.3
Moiré surfaces or backgrounds

Goods (Nice class & Statement)

5
(1) Pharmaceutical preparations for use in the prevention and treatment of infectious and inflammatory diseases, disorders, and conditions related to cancer and cancerous tumors, and oncological, inflammatory, immune, autoimmune, genetic, and rare oncological, immune, autoimmune, and genetic diseases, disorders, and conditions; anti-infectives, pharmaceutical preparations for human use, namely, pharmaceutical antibodies, pharmaceutical preparations for use in immunotherapies, pharmaceutical preparations, biological preparations, and gene therapy products in the nature of pharmaceutical and biological substances for the treatment of infectious and inflammatory diseases, disorders, and conditions related to cancer and cancerous tumors, and oncological, immune, auto-immune, genetic, and rare oncological, immune, auto-immune, and genetic diseases, disorders, and conditions, pharmaceutical preparations made from antibody-drug conjugates for conditioning patients to receive immunotherapies for the treatment of infectious and inflammatory diseases, disorders, and conditions related to cancer and cancerous tumors, and oncological, immune, auto-immune, genetic, and rare oncological, immune, auto-immune, and genetic diseases, disorders, and conditions; pharmaceutical preparations for use in the prevention and treatment of cancer and tumors.

Services (Nice class & Statement)

42
(1) Pharmaceutical drug development services; providing medical and scientific research information in the field of pharmaceuticals.
44
(2) Providing information in the fields of healthcare, therapeutic properties of pharmaceuticals, and health.

Claims

  • Priority Filing Date: November 05, 2020, Country or Office: UNITED STATES OF AMERICA, Application No. 90301364 in association with the same kind of goods and in association with the same kind of services

Action History

Actions
Action Action date Due date Comments
Filed 2021-05-03 Registration
International Registration 2021-05-03 2031-05-03
Created 2021-10-20
Formalized 2021-10-20
Designation Notification - Madrid Protocol 2021-10-21 2023-04-21
Notification of Possible Opposition Sent 2022-08-22
Search Recorded 2023-01-26
Examiner's First Report 2023-01-26 2023-07-26
Total Provisional Refusal 2023-01-26 2023-07-26
Agent Changed 2023-07-24 From/De: To/A: 69
Correspondence Created 2024-01-09 2024-07-09
Approved 2025-02-06 APPROVED BY PROGRAM EX200M1
Approval Notice Sent 2025-02-06 APPROVED BY PROGRAM EX200M1
Advertised 2025-03-05 Vol.72 Issue 3671
Opposition Start Date Notice Sent 2025-03-05 Requested on 2025/03/05 00:30:05 in program jr500m1
Registration Pending 2025-05-23
Registered 2025-05-23
Statement of Grant of Protection Sent (following a Provisional Refusal) 2025-05-23
Partial Cancellation - Madrid Protocol 2026-04-09 DP:2026-04-29 Effective date: 2026-02-26
Date modified: